Clinical Guest Contributors
-
How Close Is The First FDA-Approved Full-Spectrum Botanical Drug For Autism?
5/6/2025
AJNA BioSciences CEO Joel Stanley details his transition from helping to build one of the largest CBD companies to developing what he hopes will become an FDA-approved botanical drug to treat the symptoms of autism.
-
EMA Issues Draft Reflection Paper On Accelerating Biosimilar Approval
5/5/2025
In April, the European Medicines Agency issued a draft of a new guidance document titled Reflection paper on a tailored clinical approach in biosimilar development. The public consultation runs until Sept. 30, 2025.
-
Understanding The Impact Of An RMP On Patient Risks Using Relational Risk Analysis
5/5/2025
Using relational risk analysis, let's take a closer look at risk management plans for identifying and managing adverse reactions for administering a new therapy to a patient.
-
DEI Was Never the Problem, The Way Pharma Did It Was
5/5/2025
Consultant Denise Bronner details pharma's strategic rollback of DEI initiatives, roles, and even departments and explains why well-meaning but misguided intentions enabled their demise.
-
What The Heck Are Financial Accruals? A Guide To Understanding The Mysterious Finance Brain
5/2/2025
Clinical finance consultant Chris Chan helps clinical professionals understand financial accruals concepts and interpret requests from finance colleagues.
-
AI In Medical Devices: Meeting The Regulatory Challenge Around The World, Part 1
5/1/2025
This article explores the global regulatory landscape, examining how leading authorities in the U.S., EU, U.K., Canada, China, Brazil, Australia, and South Korea are approaching AI in medical devices.
-
7 Steps For Clinical Investigators To Implement A Robust AI Governance System
5/1/2025
In part two, Husch Blackwell LLP experts provide practical guidance for clinical investigators on overseeing the use of AI in clinical trials.
-
The Risk And Reward Of Clinical Investigators Integrating AI
5/1/2025
Husch Blackwell LLP experts discuss relevant regulatory frameworks and the risks and liabilities of clinical investigators using AI.
-
The Evolving Landscape Of Data Integrity In Good Clinical Practice
4/30/2025
ERA Sciences Andy O'Connor explores the growing focus on data integrity in good clinical practice (GCP) and how regulatory guidance is evolving to support a risk-based, system-life cycle approach.
-
Medtech CEO Shares Lessons From FIH Implantable Glucose Monitor Trial
4/30/2025
CEO and President Paul Goode, Ph.D., explores the implantable CBGM’s trial design, as well as the company’s approach to patient input, site selection, and more for its first-in-human trial.